VivoSeq
Other

Methicillin-Resistant Staphylococcus Aureus

0

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Methicillin-resistant Staphylococcus Aureus is an early-stage landscape with 0 programs across 5 companies. The most active players are Pfizer, Cumberland Pharmaceuticals, CrystalGenomics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalC

Cumberland Pharmaceuticals

0 programs

PreclinicalC

CrystalGenomics, Inc.

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed17 · 74%
Withdrawn4 · 17%
Unknown status1 · 4%
Terminated1 · 4%

Clinical Trials

Trial Activity

23 trials

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00730028·1,310 enrolled
Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization
Completed·HHorizon Health Network·N/A·NCT01438515·100 enrolled
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Completed·CCrystalGenomics, Inc.·Phase 2·NCT01593761·20 enrolled
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
Completed·Pfizer logoPfizer·Phase 4·NCT00087490·1,077 enrolled
Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting
Completed·—·N/A·NCT01232231·15 enrolled
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Completed·CCumberland Pharmaceuticals·Phase 3·NCT00107978·1,035 enrolled
Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)
Completed·HHarvard Pilgrim Health Care·N/A·NCT00980980·74,256 enrolled
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
Completed·FForest Laboratories·Phase 4·NCT01701219·56 enrolled
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00770341·122 enrolled
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
Completed·HHenry M. Jackson Foundation for the Advancement of Military Medicine·N/A·NCT01105767·30,209 enrolled
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
Completed·Bayer logoBayer·Phase 3·NCT01967225·125 enrolled
Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections
Completed·CChristiana Care Health Services·N/A·NCT00779246·1,518 enrolled
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
Completed·Pfizer logoPfizer·Phase 3·NCT00079976·174 enrolled
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
Completed·HHenry M. Jackson Foundation for the Advancement of Military Medicine·N/A·NCT00631566·550 enrolled
An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers
Completed·—·N/A·NCT00289588·3,000 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)